Krakow, Poland – 23 November 2016 – Selvita, the largest drug discovery company in Central and Eastern Europe, has published quarterly financial results showing outstanding business performance across all segments.
Net sales revenues (excl. grants) rose from PLN 10.3 MM in Q3 2015 to PLN 17.7 MM in Q3 2016, showing a 71% year-on-year increase.
Revenues from the services segment in Q3 2016 amounted to PLN 8.3 MM, representing a 40% growth in comparison to the corresponding period of the previous year, when these revenues amounted to PLN 6.0 MM
The pipeline segment generated revenues of PLN 8.5 MM, showing an exceptional increase of 117%, comparing to PLN 3.9 MM in Q3 2015.
The total revenues (incl. grants) for the first three quarters of 2016 amounted to PLN 48.9 MM, showing a healthy increase by 26% from the PLN 38.8 MM in the corresponding period Q1-Q3 2015.
The results show clearly that the company is growing strong across all divisions, enjoying continuous revenue growth.
The net profit of Selvita Group for Q3 2016 amounted to PLN 3.6 MM compared to the net profit of PLN 2.0 MM achieved in Q3 2015, indicating a 21% increase.
Full version of the Selvita Consolidated Quarterly Report for Q3 2016 is available at: https://selvita.com/investor-relations/stock-market-reports/